Impact assessments provide a structured approach to evaluating potential risks, regulatory changes, and other external factors that could affect a pharmaceutical product. This blog will explore why impact assessment is critical in the pharmaceutical product lifecycle and how it helps companies maintain compliance, reduce risks, and bring high-quality products to market.

What is Impact Assessment in Pharmaceutical Product Lifecycle Management?

An impact assessment is a systematic process of evaluating the effects of various factors on a product or process. In the context of pharmaceutical product lifecycle management, impact assessments help identify potential risks and changes that could affect a drug’s safety, efficacy, regulatory compliance, and market success. These assessments are conducted at different stages of the product lifecycle, from initial research and development to post-market surveillance.

Impact assessments in PLM typically consider factors such as:

• Regulatory changes that may require adjustments to product development or labeling.
• Market dynamics that could impact pricing, demand, or competition.
• Supply chain disruptions that could delay product availability or increase costs.
• Technological advancements that may affect drug formulation, packaging, or delivery methods.

By proactively assessing these factors, pharmaceutical companies can make informed decisions and adjust their strategies to mitigate risks and ensure that their products remain compliant and competitive.

The Stages of Pharmaceutical Product Lifecycle and the Role of Impact Assessment

The pharmaceutical product lifecycle consists of several stages, each of which presents unique challenges and opportunities. Impact assessments play a crucial role in navigating these stages successfully.

1. Research and Development (R&D)

The first stage of the pharmaceutical product lifecycle is research and development. During this phase, companies are focused on discovering new drugs, conducting preclinical studies, and developing formulations that will be safe and effective for human use.

Why Impact Assessment is Critical:

• Identifying Risks Early: Impact assessments during R&D help identify potential risks associated with drug development, such as safety concerns, ethical considerations, or regulatory hurdles. By addressing these risks early on, companies can avoid costly delays and improve the likelihood of success in later stages.
• Regulatory Compliance: As global regulatory bodies have strict guidelines for drug development, conducting an impact assessment ensures that the product development strategy aligns with regulatory requirements from the beginning, minimizing the risk of non-compliance.

2. Clinical Trials

After the R&D phase, the drug enters clinical trials, where it is tested on human subjects to evaluate its safety, efficacy, and optimal dosage. Clinical trials are divided into three phases, each with its own objectives and regulatory requirements.

Why Impact Assessment is Critical:

• Regulatory Changes: Impact assessments help companies stay up to date with any changes in clinical trial regulations, such as new guidelines from the FDA, EMA, or other regulatory bodies. Ensuring compliance with these guidelines is crucial for the successful progression of the drug through each trial phase.
• Ethical Considerations: Clinical trials must meet high ethical standards to protect participants. An impact assessment can identify potential ethical issues, such as trial design or participant consent, and ensure they are addressed before trials begin.
• Resource Allocation: Impact assessments help companies assess the potential costs and resources required for clinical trials, ensuring that they have the necessary budget and personnel to conduct trials effectively.

3. Regulatory Submission and Approval

Once a drug has successfully passed clinical trials, it must be submitted for regulatory approval. This involves preparing a comprehensive dossier that includes clinical trial data, manufacturing information, and other relevant documentation.

Why Impact Assessment is Critical:

• Meeting Submission Requirements: Impact assessments ensure that all necessary documents and data are included in regulatory submissions. Missing or incomplete information can lead to delays in approval, so it’s critical that companies conduct thorough assessments to avoid such issues.
• Evaluating Market Potential: Before submitting a drug for approval, companies need to assess the potential market impact. This includes analyzing the competitive landscape, pricing strategies, and potential demand for the drug. An impact assessment helps identify opportunities and risks, allowing companies to adjust their market strategy as needed.
• Global Compliance: Impact assessments are especially important for companies seeking approval in multiple regions, as they must comply with different regulatory requirements in each market. Conducting an impact assessment ensures that the product meets the standards of each regulatory body.

4. Product Launch

After receiving regulatory approval, the drug is ready for market launch. This phase involves manufacturing, marketing, and distribution efforts to bring the product to consumers.

Why Impact Assessment is Critical:

• Supply Chain Readiness: Impact assessments can help identify potential bottlenecks or disruptions in the supply chain that could delay the product launch. This is particularly important for ensuring that the product is available in sufficient quantities to meet market demand.
• Market Strategy Adjustment: Impact assessments can reveal changes in market conditions, such as new competitors, pricing shifts, or changes in consumer behavior. By evaluating these factors, companies can adjust their marketing and distribution strategies to optimize the product launch.
• Compliance Monitoring: Even after the product is launched, regulatory requirements must continue to be met. Impact assessments help monitor compliance with labeling, marketing claims, and post-market surveillance requirements, reducing the risk of regulatory action.

5. Post-Market Surveillance

After the product is on the market, it is subject to ongoing monitoring to ensure that it remains safe and effective. This includes tracking adverse events, monitoring product performance, and responding to regulatory updates.

Why Impact Assessment is Critical:

• Adverse Event Monitoring: Impact assessments help companies track and respond to adverse events reported by healthcare providers or patients. If any safety concerns arise, an impact assessment can guide decision-making regarding product recalls, labeling changes, or additional warnings.
• Regulatory Updates: As regulatory requirements evolve; impact assessments help companies stay compliant by identifying new regulations that may affect their product. For example, new labeling requirements or changes in post-market reporting standards can be addressed through a well-conducted impact assessment.
• Product Lifecycle Management: Impact assessments are essential for managing the entire product lifecycle, including decisions about product updates, discontinuation, or the introduction of new formulations. By evaluating market performance and regulatory factors, companies can make informed decisions about the future of their products.

The Benefits of Conducting Regular Impact Assessments in PLM

Conducting regular impact assessments throughout the product lifecycle offers numerous benefits to pharmaceutical companies, including:

• Risk Mitigation: By identifying potential risks early, companies can take proactive steps to address them, reducing the likelihood of costly mistakes or delays.
• Improved Decision-Making: Impact assessments provide valuable insights into market conditions, regulatory requirements, and other factors that influence product success. This enables companies to make informed decisions about product development, launch, and lifecycle management.
• Regulatory Compliance: Regular impact assessments help ensure that companies remain compliant with regulatory requirements, reducing the risk of fines, product recalls, or delays in approval.
• Enhanced Market Competitiveness: By evaluating market dynamics and adjusting strategies accordingly, impact assessments help companies maintain a competitive edge and maximize the commercial potential of their products.

Conclusion

Impact assessment is a critical component of pharmaceutical product lifecycle management. From R&D to post-market surveillance, conducting thorough impact assessments at each stage helps companies mitigate risks, ensure regulatory compliance, and optimize product success. As the pharmaceutical industry continues to evolve, the importance of impact assessments will only grow, making them an essential tool for any company looking to succeed

In this blog, we’ll delve into what regulatory publishing automation is, why it’s essential for modern businesses, and how it’s reshaping the future of compliance. We’ll also explore specific benefits, real-world applications, and the potential hurdles to implementing these automated systems.

What is Regulatory Publishing Automation?

Regulatory publishing automation refers to the use of advanced technologies and software solutions to streamline the process of creating, managing, and submitting regulatory documents. This technology automates manual tasks such as data entry, document formatting, and submissions to regulatory bodies. It ensures that all documents meet the necessary regulatory requirements, reducing errors and improving efficiency.

This type of automation is crucial for industries with stringent regulatory guidelines, including pharmaceuticals, biotechnology, medical devices, and finance, where even minor errors can result in costly delays or penalties.

Why Has Automation Become Essential?

The need for automation in regulatory publishing stems from several key factors:

1. Increasing Complexity of Regulations: As global regulations become more stringent and varied across regions, keeping up with the latest updates manually can be overwhelming.
2. Time-Consuming Processes: Traditional manual methods of preparing regulatory documents are slow and prone to human error, which can cause delays in product launches or approvals.
3. Costly Errors: Mistakes in regulatory submissions can lead to severe financial penalties and even damage a company’s reputation.
4. Need for Global Compliance: Companies often need to comply with regulations in multiple jurisdictions, which makes manual tracking and updates highly inefficient.

Automation not only addresses these challenges but also offers numerous advantages that can significantly enhance the efficiency of the regulatory process.

Key Benefits of Regulatory Publishing Automation

The automation of regulatory publishing offers a wide range of benefits that make it an attractive option for organizations. Let’s explore some of these key advantages in detail.

1. Improved Efficiency and Speed

Manual processes in regulatory publishing can take up valuable time, especially when it involves gathering information from multiple sources, formatting documents, and submitting them for approval. Automation allows companies to reduce the time spent on these tasks significantly. This means faster submissions, quicker approvals, and more time to focus on other core business activities.

2. Enhanced Accuracy and Compliance

Automated systems are designed to follow predefined rules and protocols, which minimizes the risk of human errors. By automating data entry, formatting, and document verification, companies can ensure that their regulatory submissions are always accurate and meet the latest compliance standards.

3. Streamlined Collaboration

Regulatory publishing often involves input from multiple departments and teams. An automated platform makes it easier for stakeholders to collaborate by providing a centralized system where all team members can access and contribute to documents in real-time, ensuring consistency and reducing miscommunication.

4. Cost Savings

By reducing the time and resources needed to prepare and submit regulatory documents, automation leads to significant cost savings. Fewer errors also mean fewer costly revisions and resubmissions, further enhancing a company’s bottom line.

5. Scalability

As companies grow and expand into new markets, the volume of regulatory submissions can increase dramatically. Manual processes may struggle to keep up with this demand. However, automated systems are highly scalable, making it easier for businesses to handle growing compliance requirements without sacrificing efficiency.

How Regulatory Publishing Automation Works

Automation in regulatory publishing typically involves several components working together to optimize the entire process. Let’s break down how these systems function and the key features that make them so effective.

1. Document Management and Formatting

Automated platforms can handle a wide variety of document types and formats. These systems standardize the formatting of documents based on regulatory requirements, ensuring that submissions are consistent and meet the guidelines of specific regulatory bodies.

2. Data Integration

One of the most powerful aspects of automation is its ability to integrate data from multiple sources, such as internal databases, research systems, and external partners. This eliminates the need for manual data entry, reducing errors and ensuring that information is always up-to-date.

3. Real-Time Updates

Regulatory requirements are constantly changing, which can make it challenging for organizations to keep track of the latest updates. Automated systems can automatically update compliance protocols based on the latest regulatory changes, ensuring that submissions are always in line with current standards.

4. Automated Submissions

Once the regulatory documents are prepared, automated systems can handle the actual submission process. They ensure that documents are sent to the appropriate regulatory bodies in the correct format and within the required timeframe, reducing the risk of delays or missed deadlines.

Industries Benefiting from Regulatory Publishing Automation

While regulatory publishing automation can benefit almost any industry, it has proven particularly valuable in certain sectors where compliance is critical. Let’s take a closer look at some of these industries.

1. Pharmaceuticals and Biotechnology

In the pharmaceutical industry, regulatory submissions are a crucial part of bringing new drugs to market. Automation allows companies to accelerate the process of preparing and submitting documentation to regulatory authorities like the FDA and EMA, ensuring that products can be approved more quickly.

2. Medical Devices

Medical device manufacturers must comply with stringent regulations to ensure the safety and effectiveness of their products. Automated systems help these companies manage their regulatory submissions efficiently, reducing the time it takes to get new devices approved and onto the market.

3. Finance and Banking

Financial institutions are subject to a variety of regulatory requirements related to transparency, risk management, and reporting. Automation enables these companies to handle complex regulatory submissions, such as reports to government agencies, with greater speed and accuracy.

4. Healthcare

Healthcare organizations must adhere to numerous regulations, especially related to patient data and privacy. Automated regulatory publishing ensures that these organizations can quickly respond to changing regulations and submit the necessary documentation without errors.

Challenges in Implementing Regulatory Publishing Automation

Despite the clear benefits of regulatory publishing automation, there are still challenges that organizations may face when adopting these systems. Understanding these hurdles can help businesses better prepare for implementation and maximize the value of their automation investment.

1. High Initial Investment

Implementing automated systems often requires a significant upfront investment in software, hardware, and training. While the long-term benefits can far outweigh the initial costs, this can be a barrier for smaller organizations with limited budgets.

2. Integration with Existing Systems

Many organizations already have legacy systems in place for managing their regulatory documents. Integrating new automated platforms with these existing systems can be complex and time-consuming, requiring careful planning and execution.

3. Resistance to Change

Introducing automation can sometimes lead to resistance from employees who are accustomed to traditional manual processes. Effective change management and clear communication about the benefits of automation are essential for overcoming this resistance.

4. Keeping Up with Regulatory Changes

While automation can handle real-time updates to regulatory requirements, it’s essential for companies to stay informed about changes in their industry. Relying too heavily on automation without proper oversight can lead to gaps in compliance if updates are not properly integrated into the system.

How to Choose the Right Regulatory Publishing Automation Solution

Selecting the right automation platform is a crucial decision that can impact the success of your regulatory publishing efforts. Here are some factors to consider when evaluating different solutions.

1. Customization

Every industry and organization has unique regulatory requirements. Look for a solution that can be customized to meet your specific needs and workflows, ensuring that the system aligns with your business processes.

2. Scalability

Choose a platform that can scale with your business as you grow. As your regulatory needs expand, your automation system should be able to handle an increasing volume of submissions without compromising on efficiency.

3. Support and Training

Ensure that the vendor provides comprehensive support and training to help your team get up to speed with the new system. This is especially important for overcoming any resistance to change and ensuring a smooth transition to automated processes.

4. Compliance with Industry Standards

Make sure that the automation platform complies with the latest industry standards and regulations in your sector. This will help ensure that your submissions are always in line with current regulatory requirements.

The Future of Regulatory Publishing Automation

The future of regulatory publishing lies in advanced automation technologies such as artificial intelligence (AI) and machine learning (ML). These technologies can further enhance the capabilities of automated systems by learning from past submissions, predicting future compliance needs, and providing actionable insights to improve the overall process.

As businesses continue to adopt these cutting-edge technologies, we can expect regulatory publishing to become even more efficient, accurate, and scalable. In the near future, fully automated regulatory publishing may become the industry standard, helping companies navigate the complex world of compliance with ease.

Conclusion

Regulatory publishing automation is no longer a luxury – it’s a necessity for businesses in highly regulated industries. By streamlining the preparation and submission of regulatory documents, automation enables organizations to reduce errors, improve efficiency, and stay compliant with ever-changing regulations. Whether you’re in pharmaceuticals, finance, or healthcare, investing in

In this blog, we’ll explore the importance of automation in regulatory publishing during the transition to eCTD 4.0, highlight its benefits, and explain why businesses need to adapt to this new regulatory framework.

What is eCTD 4.0?

The Electronic Common Technical Document (eCTD) is an internationally recognized standard used by regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others for the submission of pharmaceutical and healthcare product information. It streamlines the submission process by organizing data in a standardized electronic format that regulatory bodies can review efficiently.

eCTD 4.0, the latest version of this format, introduces several significant enhancements, including:

• Increased data granularity for easier navigation and review of submissions.
• Enhanced metadata and tracking, improving the efficiency of submission lifecycle management.
• Better version control and traceability of regulatory submissions.

As regulatory bodies begin mandating the use of eCTD 4.0, businesses need to transition from earlier versions to remain compliant. This shift requires a major overhaul of how submissions are prepared and submitted, which can be a complex and time-consuming process. This is where automation comes into play.

The Role of Automation in Regulatory Publishing

Regulatory publishing automation is the process of using technology to streamline the creation, management, and submission of regulatory documents. Automation helps organizations manage complex workflows, ensure compliance with global regulatory requirements, and maintain submission timelines.

The transition to eCTD 4.0 adds new layers of complexity to regulatory submissions, making automation even more essential. Here’s how automation can help:

1. Simplifying Complex Submission Processes

With the enhanced structure and data granularity in eCTD 4.0, manually preparing submissions can be overwhelming. Automation tools can simplify this process by organizing data into the required structure automatically, ensuring that all necessary elements are properly formatted and included.

Automated systems are designed to adhere to specific guidelines, so businesses can avoid costly errors caused by manual data entry, incorrect formatting, or missing documentation. As a result, teams can focus on higher-value tasks, rather than getting bogged down in the intricacies of submission preparation.

2. Ensuring Compliance with Global Regulations

As regulations vary across different regions, companies submitting products in multiple markets must ensure that their documents comply with each country’s specific requirements. This becomes especially challenging with the adoption of eCTD 4.0, as new submission rules may apply depending on the region.

Regulatory publishing automation platforms are designed to stay up to date with global regulations, including those associated with eCTD 4.0. This helps companies ensure that their submissions are always compliant, reducing the risk of rejections or delays.

3. Improving Submission Accuracy and Consistency

One of the most significant challenges in regulatory publishing is maintaining accuracy and consistency across submissions. With eCTD 4.0 requiring greater detail and organization, mistakes can lead to submission delays or rejections.

Automation tools improve accuracy by eliminating the manual tasks that are prone to human error. They ensure that documents are consistently formatted, correctly tagged with metadata, and properly organized, reducing the chances of costly mistakes.

4. Speeding Up the Submission Process

Preparing a regulatory submission can be a lengthy process, particularly when multiple teams are involved. By automating many of the time-consuming aspects of submission preparation, such as document compilation, validation, and formatting, companies can significantly speed up the process.

This is especially important during the transition to eCTD 4.0, where timelines may be tight. Automation ensures that submissions are completed more quickly and efficiently, reducing the time it takes to bring a product to market.

5. Real-Time Updates and Integration with eCTD 4.0 Requirements

One of the key features of eCTD 4.0 is its ability to support more dynamic updates and modifications to submissions. Automation tools can provide real-time updates to submission statuses, ensuring that all stakeholders are informed throughout the process. Additionally, automated platforms can integrate with eCTD 4.0’s enhanced metadata and tracking capabilities, making it easier for organizations to manage the submission lifecycle from start to finish.

Challenges of Transitioning to eCTD 4.0 Without Automation

While transitioning to eCTD 4.0 is mandatory for compliance, doing so without the assistance of automation can present significant challenges. Here are some potential pitfalls that organizations may face when relying on manual processes during this transition:

1. Increased Complexity

eCTD 4.0 introduces more detailed submission requirements and additional metadata, which can make manual processes far more cumbersome. Without automation, businesses run the risk of missing crucial details, leading to incomplete or incorrect submissions.

2. Higher Risk of Errors

Manual data entry and document formatting leave room for human error, which can delay the approval process or result in costly rejections. Automation minimizes the chances of errors by automating repetitive tasks and ensuring compliance with submission standards.

3. Time-Consuming Processes

The complexity of eCTD 4.0 submissions means that manual preparation can take longer than ever before. Without automation, companies may struggle to meet submission deadlines, especially when dealing with multiple jurisdictions and regulatory authorities.

4. Lack of Scalability

As companies grow and submit products in multiple regions, the volume of regulatory submissions can increase exponentially. Manual processes are not scalable, which can create bottlenecks and slow down the entire compliance process. Automation offers scalability, allowing businesses to handle a growing number of submissions without compromising on efficiency or accuracy.

How to Leverage Automation for eCTD 4.0 Submissions

To successfully transition to eCTD 4.0 and take full advantage of automation, companies should consider the following steps:

1. Choose the Right Regulatory Automation Platform

Selecting a regulatory automation platform that is compatible with eCTD 4.0 is critical. Look for a solution that offers customizable workflows, real-time updates, and the ability to integrate with other systems to streamline the submission process.

2. Ensure Global Compliance Capabilities

Given that regulations vary across different regions, choose a platform that supports global compliance. The right automation solution should stay up to date with regulatory changes across all jurisdictions where your company operates.

3. Train Your Teams on Automation Tools

While automation simplifies many processes, it’s important to ensure that your teams are trained to use the new tools effectively. Investing in training can help your staff understand how to maximize the benefits of automation and ensure a smooth transition to eCTD 4.0.

4. Plan for Continuous Updates and Compliance Monitoring

Regulatory landscapes are always evolving, and compliance standards will continue to change. Choose a regulatory publishing automation solution that offers continuous updates to keep up with changes in eCTD 4.0 requirements and other global regulations.

Conclusion

The transition to eCTD 4.0 presents both challenges and opportunities for organizations in regulated industries. By leveraging regulatory publishing automation tool REGai, businesses can simplify complex submission processes, ensure global compliance, improve accuracy, and accelerate timelines. Automation is no longer a luxury; it’s a necessity in today’s regulatory environment. As the world shifts to eCTD 4.0, companies that adopt automation will be better positioned to navigate the new landscape with confidence, ensuring that their products reach the market faster and with fewer risks.

An UDI is a distinct numeric or alphanumeric code used to identify medical devices throughout healthcare supply chains. These codes are generated by product owners based on globally accepted standards for device identification.

The UDI code consists of two standard elements, which are:

• Device Identifier (DI): DI identifies the labeler and the model or version of a device. The DI is a required component and considered to be the static portion of the UDI, meaning that it is the same for all instances of the product model or version.
• Production Identifier (PI): PI identifies one or more variable characteristics, such as manufactured date, expiration date, lot number, or serial number. The PI is considered to be the dynamic portion of the UDI, meaning that the PI value changes according to the production controls.

The DI is always first and is followed by the PI if it has a value.

Unique Device Identifier (UDI) = Device Identifier (DI) + Production Identifier (PI)

There are different Issuing Agencies/ Entities for issuing an UDI for a medical device they are:

GS1: Global Standards 1 (GS1) are a nonprofit standards agency, GS1 sets international standards for supply chains, electronic data exchange, healthcare, and more. GTIN (Global Trade Item Number) and UPC (Universal Product Code) are GS1 standards, both are numeric only codes. GS1 provides a “GS1 Company Prefix” to a subscribing organization and reserves a range of “Item Reference” numbers for the organization to assign to their product portfolio. GS1 charges an initial fee and a lower annual renewal fee for the subscription. GS1 is used by the majority of medical device manufacturers.

HIBCC: Health Industry Business Communications Council (HIBCC) is a nonprofit organization focused on setting standards for the healthcare industry. The HIBC (Health Industry Bar Code) standard is managed by HIBCC and is an alphanumeric code. HIBCC provides a Labeler Identification Code (LIC) to an organization after paying a one-time subscription fee. The organization creates and assigns Product/Catalog Numbers (PCN) to their product portfolio without an additional charge.

ICCBBA: International Council for Commonality in Blood Banking Automation (ICCBBA) is a non-governmental organization. ICCBBA focuses exclusively on standards for medical products of human origin, such as blood products, tissues, and organs for transplant. It manages the ISBT 128 standard used in more than 75 countries. Only a few niche medical devices are identified using the ICCBBA standard.

Issuing Agency standards typically define a device identifier to encode a company, a product model, a package level, and a check character used to verify the accuracy of the code. 

UDI codes are included on the product and package labels and, in some cases, printed directly on the device itself. Regulations require the UDI be presented in both Automatic Identification and Data Capture (AIDC) and Human Readable Interpretation (HRI) formats.

The AIDC format is a one- or two-dimensional barcode. This format allows the product to be identified quickly and accurately by using barcode readers and scanner technologies. The HRI text format refers to easily readable text that allows the product to be identified by humans without the use of any scanning or barcode reader technology.

In the case of reused and reprocessed devices, such as a surgical scalpel, the UDI must be directly marked on the product, as the product packaging is discarded. There are different direct marking technologies such as laser etching, to mark the product for the life of the product.

Once the UDI is issued, the data must be securely stored in the manufacturer’s repository and submitted to the respective health authority’s Unique Device Identification Database (UDID).

In general, regulations require product UDI data to be reported to the UDID before the medical device is placed on the market. The UDI Device Identifier and numerous other data attributes need to be collected and submitted to the UDID.

An increasing number of health authorities are implementing UDI requirements to improve patient safety and the patient experience. Accurate, comprehensive product information gleaned from UDIDs is essential to ensure the correct and safe use of devices by all users, including patients, caregivers, healthcare providers, hospitals, and industry.

The primary goal of a UDI system is to ensure proper adverse event reporting among medical devices. UDI increases the accuracy of product traceability and enables medical device manufacturers, regulatory bodies, and other analysts to discover trends earlier and respond quicker in the event patient safety is at risk due to a certain device issue.

In order to effectively streamline UDI labeling and submissions for your medical devices, it is essential to have a thorough understanding of the entire process of development, validation, design, and submission of requirements. DDi offers a single Unique Device Identification (UDI) solution that meets compliance requirements across all countries.

In general, an eIFU is defined as a non-paper version of the instructions for use. Currently, the definition of an eIFU is not the same in each market.

In the EU, according to the Commission Implementing Regulation EU 2021/2226, which laid down rules for the application of Regulation (EU) 2017/745 of the European Parliament and of the Council in regards to electronic instructions for use of medical devices, instructions for use in electronic format means “instructions for use displayed in electronic form by the device, contained in portable electronic storage media supplied by the manufacturer together with the device, or made available through software or website.”

European eLabeling regulation 2021/2226 

The Medical Device Regulation (MDR) introduces a comprehensive framework that integrates multiple electronic instructions for use (eIFU) requirements, further supplemented by Implementing Regulation (EU) 2021/2226, the successor to Commission Regulation (EU) 207/2012.

Requirements for the use of electronic instructions for use as per regulation (EU) 2021/2226 

According to Implementing Regulation (EU) 2021/2226, instructions for use may be provided electronically (eIFU) instead of on paper if certain conditions are met:

1. The device should fall into a specific class, as mentioned below:
   • Implantable and active implantable medical devices and their accessories
   • Fixed installed medical devices and their accessories
   • Medical devices and their accessories fitted with a built-in system visually displaying the instructions for use (e.g., ultrasound equipment)
2. The devices and accessories are intended for exclusive use by professional users
3. The use by other  people is not reasonably foreseeable
4. For software, manufacturers may provide eIFUs within the software itself.

Manufacturers of Medical devices that provide instructions for use in electronic form to users instead of in paper form shall undertake a documented risk assessment which shall cover at least the following elements:

• Knowledge and experience of the intended users in particular regarding the use of the device and user needs;
• Characteristics of the environment in which the device will be used;
• knowledge and experience of the intended user of the hardware and software needed to display the instructions for use in electronic form;
• Access of the user to the reasonably foreseeable electronic resources needed at the time of use;
• Performance of safeguards to ensure that the electronic data and content are protected from tampering;
• Safety and backup mechanisms in the event of a hardware or software fault, particularly if the instructions for use in electronic form are integrated within the device;
• Foreseeable medical emergency situations requiring the provision of information in paper form;
• Impact caused by the temporary unavailability of the specific website, of the internet in general, or of their access in the healthcare institution, as well as the safety measures available to cope with such a situation;
• Evaluation of the period within which the instructions for use shall be provided in paper form at the user’s request;
• Assessment of the website’s compatibility with displaying the electronic instructions for use with different devices that could be used to display those instructions;
• Management of different versions of the instructions for use, where applicable

Factors to consider when switching to an electronic IFU for your medical device

1. Risk assessment

eIFU must maintain or improve the level of safety compared to providing a paper IFU. Your risk assessment needs to examine this carefully. For instance, if your device is sometimes used by nurses or doctors in rural locations where the internet may be spotty, what additional risks might that present? You will need to update your risk management procedures and forms to account for this.

2. Product packaging

The location of the eIFU must be indicated on the packaging for each unit or, in the case of fixed devices, on the device itself. For obvious reasons, you cannot simply place PDFs of your IFU on your website and assume professional users will know to look there. The Regulation makes it clear that your packaging must clearly specify that the IFU is in electronic format and where it can be found. Except for software and devices with screens, the IFU may reside on a website, and its location may be communicated via a website URL or QR code. If you choose the latter, make sure you document the pros and cons of using QR codes in your risk assessment and update your labeling work instructions as needed.

3. Validation

Ensure the user’s access is precise by having accurate product data in real-time and a solution for delivering the information in the user’s preferred language.

4. Method of delivery

If you make software as a medical device (SaMD) or a device with a larger display screen, the method of delivery may be the device itself. For all other devices, device manufacturers will most likely deliver IFUs via their website. This fulfills a key requirement that the information be provided in a universally available format (thumb drives and DVDs are no longer universal). The preamble of the new eIFU regulation says, “To ensure unconditional access to the instructions for use in electronic form and to facilitate the communication of updates, those instructions should be available on the website of the manufacturer in an official language of the Union determined by the Member State in which the device is made available to the user or patient.” This does not mean you cannot deliver your eIFU on a private YouTube channel, for example.

5. Paper version

There are professionals out there who prefer paper-based instructions, or (it is true) might not have reliable internet access. It is EU law to have paper IFUs, with the exception of some devices. If a paper-based option is required, you are obligated to provide a paper version within seven calendar days of the request at no cost. In cases where video or animation is not used, the eIFU may simply be a printed copy of the PDF you maintain online. Make sure to update your labeling SOP with this requirement.

6. Online security

Making your IFU available online is easy. Ensuring that it does not accidentally get removed or replaced is not possible. You will need to put procedures in place to ensure that your sales and marketing departments do not change the URL, delete old versions, or otherwise change the document. You should really think of the master IFU web page(s) as controlled documents, not just the IFU itself.

7. Archival procedures

For devices without a defined expiration date, your IFU needs to be maintained for 15 years after the last device has been placed on the market. For devices with an expiration date, this changes to 10 years. You also need to have a system for indicating when changes have been made (change control) and a way to inform each user if the change was made for safety reasons. Finally, all historical versions of the IFU must be made available on the website.

8. Privacy policy

Europe has one of the strictest online privacy laws in the world, known simply as the GDPR (General Data Protection Regulation 2016/679). If you will be asking the user to provide their name and/or email, or if your website has cookies enabled (most do), you will need to make sure you are following the GDPR.

Advantages of eIFU over paper-based instructions:

• Enhanced accessibility: considering the high internet coverage, electronic instructions can be accessed digitally and consulted anywhere, providing easier search and navigation and greater flexibility.
• Real-time updates: eIFU allows for immediate updates and revisions, ensuring that users always have the latest information about the product they are using. This is crucial for patient safety and optimal device utilization.
• User-friendly interfaces: Electronic formats enable the incorporation of multimedia elements, such as videos and interactive features, enhancing the clarity and effectiveness of instructions.
• Increased efficiency in MDR implementation: electronic formats facilitate the inclusion of multiple languages and therefore contribute to reducing the risk of shortages of medical devices and improving the overall availability of these devices, especially in a multilingual context like the European Union.
• Cost efficiency: Over time, the implementation of eIFU can lead to cost savings for both manufacturers and healthcare institutions, as the need for printing, distribution, storage, and waste management of paper IFU is significantly reduced.
• Environmentally sustainable: The transition to eIFU aligns with broader efforts to reduce paper usage, contributing to environmental sustainability and supporting the EU Green Deal.

Going forward, manufacturers seeking to sell their products in the European market must comply with the EU eIFU regulations. Adhering to these regulations will provide greater flexibility and reduce the risk of product recalls related to IFUs. If you are in the process of updating your device labels and preparing eIFUs, feel free to contact DDi for expert assistance.